Furthermore, in the HER2-low group, the proportion of patients who experienced recurrence or metastasis within two years of the initial breast cancer diagnosis was relatively lower compared to the HER2-0 group (45.9% vs. 60.5%, p=0.055). Here, ERBB2 is linked to breast cancer.